Search results
Results from the WOW.Com Content Network
The sale will bring down GSK's current 10.3% holding in the Sensodyne maker, which was spun out and listed on the London Stock Exchange in July 2022. GSK earlier this year sold 240 million shares ...
GSK sold around 385 million shares at 324 pence apiece, amounting to a 4.2% stake in Haleon. ... Haleon, in which GSK initially had a nearly 13% stake, was spun out and listed on the London Stock ...
The latest offload will mark the fourth set of disposal GSK has had in the Sensodyne toothpaste maker in a year. GSK, which initially retained a near 13% stake in Haleon, had over the course of a ...
Haleon has been focused on cutting debt by selling brands such as Lamisil and Chapstick and keeping a lid on costs. After being spun-off from drugmaker GSK in 2022, it cut debt by over 2 billion ...
Haleon was established on 18 July 2022 as a corporate spin-off from GSK. [6] Sir Dave Lewis is chairman, with Brian McNamara as CEO. [7] Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in ...
Shares in Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019 and spun off from the British drugmaker in 2022, fell 1.2% to 388 pence in morning ...
Haleon Plc (NYSE: HLN) notified GSK Plc (NYSE: GSK) and Pfizer Inc (NYSE: PFE) that it had rejected their requests for indemnification concerning U.S.-based litigation over the heartburn drug, Zantac.
British drugmaker GSK spun off its consumer health business on Monday in the biggest listing in Europe for more than a decade, but the unit's market value of 30.5 billion pounds fell well short of ...